Firering Strategic Minerals: From explorer to producer. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
1.2m suffer and it is increasing debrief and one other drug available.
https://www.businesswire.com/news/home/20191104005337/en/Global-Idiopathic-Pulmonary-Fibrosis-IPF-Market-Spotlight
From the RNS showing the initial results of NXP002 it shows NXP002 outperforming esbriet. There is only one other drug currently available for IPF treatment and that is Ofev .
Which is better OFEV or Esbriet?
Results showed that the already approved therapies offered more reliable and positive results. Esbriet, at the recommended dose of 2403 mg/day, was found to be more effective than 300 mg/day of Ofev.17 Jul 2017
Hard to believe anyone could drive this price this low if the results of NXP002 are better than current treatments in such a large market. Hope they are progressing clinical tests while we await Japan news.
Cost of OFEV
The cost for Ofev oral capsule 100 mg is around $10,955 for a supply of 60 capsules, depending on the pharmacy you visit. Prices are for cash paying customers only and are not valid with insurance plans. Ofev is available as a brand name drug only, a generic version is not yet available.
https://www.drugs.com › ... › Ofev
Ofev Prices, Coupons & Patient Assistance Programs - Drugs.com
Thanks Mars1 - it's a wanted product alright. Exciting times. They are smart folk at Nuformix. Choose their drug carefully for how it can be improved and where there is high commercial benefit. As the market collapses in freefall (who knows where the bottom is there), the advanced talks continue, agreed in principle, as data is being gone through diligently. The Japanese pharma company want it and Dr Gooding says he is happy with where things are. We may have other news on other things before NXP002 too - but sure as I have a coffee every morning, progress is being made.
OFEV is Nintedanib and apparently has a number of side effect including severe renal impairment and liver impact so not surprising patients stop taking treatments.
General warnings for Nintedanib
Contraindications:
Moderate to severe hepatic impairment. Peanut or soya allergy. Pregnancy; ensure hormonal and barrier contraception and continue for =3 months after treatment. Lactation.
Warnings:
Mild hepatic or severe renal impairment (CrCl <30ml/min). Perform LFTs before and during treatment, discontinue permanently if signs of liver injury occur. Monitor renal function esp in patients with risk factors for renal impairment. Predisposition to bleeding. Increased cardiovascular risk; consider treatment interruption if signs of myocardial ischaemia occur. Previous abdominal surgery; do not start treatment for =4 weeks after surgery, discontinue permanently if GI perforation occurs. History of peptic ulceration or diverticular disease. Risk of aneurysm or artery dissection. Monitor BP. Risk of impaired wound healing. Risk factors for QT prolongation.
https://www.mims.co.uk/drugs/respiratory-system/cough-congestion-respiratory-distress/ofev
Hopefully NXP002 is a real benefit to patients
That was another thing of their 2018 data findings that they said: 'gives us confidence in our ability to both inhibit fibrosis and attenuate inflammation in patients without these side effects'. https://nuformix.com/app/uploads/2018/12/NFX-NXP002-IPF-Results-RNS-FINAL.pdf - no wonder they are in advanced talks.
Hopeabound
While I certainly hope what you say is true, what 's the factual basis for your post?
Another great post Aim, I’m locked into this and keep buying into the dips with glee. It does me the favour of averaging down my price & buying into a great future. It doesn’t matter to me if it’s weeks, months or years. I know what I’m investing into here, that is something that is huge judging by the data and patents. Don’t think a lot of people have a real grasp of what is going on here. Waiting patiently for the BOD to bring it to fruition.
Thanks Aim for reposting previous RNS's .
As I have invested my actual money here, yes I have read and done my research.
My question to Hopeabound was on what factual basis did he quote the following:
"We may have other news on other things before NXP002 too - but sure as I have a coffee every morning, progress is being made."
As this made it sound like he was saying he had definitive information that this was actually so rather than supposition. I would rather hear fact than supposition when it comes to my investment.
Hi Albi1.
I personally find the re-posting of RNSs useful - they remind me of all the things I have looked at previously but may not have remembered. They also come with a little explanation from Aim4utopia which I also find useful. Plus, some people coming on here may not have done that research and they see it presented for them.
Regarding that one sentence you have decided to pluck out. I was saying it with such comfortableness because Dan said the word progress a couple of times it in his podcast.
He said the raise "allows us to progress NXP002 and NP004 programmes."
Regarding impact of coronavirus, he said: "It's not effecting us at the moment. We're able to progress things...things are going just fine."
"This is a very technical negotiation with exchange of data in both directions but I'm really pleased with where things are. We're working on the best deal for all stakeholders."
'We're working', not were working or have been working but 'we're'. That is the language of progress being made.
Regarding other news. I am not alone on here, in thinking we may and it was the word 'may' I used, receive other news.
A very exciting time ahead for my biggest investment.
Hopeabound
Thanks for taking the time to reply. I was interested to know if you had come across information that gave you that level of certainty other than the podcasts etc. This is now also my largest investment so we're on the same page!
I clicked through to the link that Aim helpfully provided on the NXP002 patent & was amazed to see its potential uses outside of fibrotic treatment, this caught my eye:
"It has been reported that tranilast has the ability to induce or enhance neurogenesis and, therefore, could be used as an agent to treat neuronal conditions such as .... multiple sclerosis, amyotrophic lateral sclerosis, Alzheimer'"'"'s disease..."
I’m also quite excited about the prospect of NXP004, and what that entails. Although the recent update said it was promising didn’t get much of a follow through as of yet. So hopefully we can get some added info which will take this to another level together with the anticipated licensing.
Mohsin, why are you excited about NXP004? Do you know what it does?
Buy, take a bit of profit on big news and hold the rest for a couple of years when NFX will be sold for many, many, many, many, many and many multiples of today's current share price. Dan has already said they're building the company up to sell it in the near future therefore don't listen to the noise just hold and wait to be highly rewarded.
Soup, this bit from Dan Got me excited. ‘NXP004 introduces a strong new candidate to our development pipeline which we believe offers significant commercial potential in multiple therapeutic areas.' https://www.share-talk.com/nuformix-plc-lonnfx-ceo-dr-dan-gooding-interview/#gs.yqf3xt. Also the words Significant & multiple. DYOR
Indeed Moshin, but that's far in the future, they've not even filed its patent yet, NXP001 & 002 will provide near term excitement.
Are you an insider then Aim?
From memory, Dan said even though they're working on NXP004 in the background, he didn't expect there to be substantial news on this one until end of Q2. Well that's only 4 months away now so it soon be here.